Effective Treatment of Refractory Pulmonary Hemorrhage with Monoclonal Anti-CD20 Antibody (Rituximab)

Publisher： Karger

E-ISSN： 1423-0356|78|1|106-109

ISSN： 0025-7931

Source： Respiration, Vol.78, Iss.1, 2008-09, pp. : 106-109

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 491-494

Karger

Access to resources Recommend Favorite

Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 691-693

Karger

Access to resources Recommend Favorite

Rituximab (Anti-CD20 Monoclonal Antibody) Administration in a Young Patient with Resistant B-Prolymphocytic Leukemia

By  

Acta Haematologica, Vol. 102, Iss. 2, 1999-10 ,pp. : 94-98

Karger

Access to resources Recommend Favorite

Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 351-354

Karger

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite